SPIN Processed Press Release Frame: The Cushion
Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
A Phase 3 clinical trial (EVOKE-03/KEYNOTE-D46) testing sacituzumab govitecan plus pembrolizumab in first-line PD-L1-high metastatic NSCLC failed to meet its primary endpoints of progression-free survival and overall survival, though it showed numerically improved but statistically non-significant outcomes.
Spin 72% Claim Present in Source AI Risk Moderate
What AI may repeat
"Sacituzumab govitecan plus pembrolizumab showed numerically improved progression-free survival in first-line NSCLC but missed primary endpoints."
PR Newswire Technology
Sep 13, 2026